ABCL logo

AbCellera Biologics (ABCL) Company Overview

Profile

Full Name:

AbCellera Biologics Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

Canada

IPO:

December 11, 2020

Indexes:

Not included

Description:

AbCellera Biologics is a biotechnology company that focuses on discovering and developing antibody therapies. They use advanced technology to analyze immune responses and identify potential treatments for diseases, including cancer and infectious diseases. Their goal is to accelerate the development of new medicines for patients.

Events Calendar

Earnings

Next earnings date:

May 7, 2025

Recent quarterly earnings:

Feb 27, 2025

Recent annual earnings:

Feb 27, 2025
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Feb 28, 25 Stifel
Buy
Jan 8, 25 Keybanc
Overweight
Nov 5, 24 Stifel
Buy
Nov 5, 24 Benchmark
Hold
Aug 20, 24 Benchmark
Hold
Jul 11, 24 Keybanc
Overweight
May 8, 24 Keybanc
Overweight
Feb 22, 24 Benchmark
Buy
Feb 21, 24 Stifel
Buy
Dec 5, 23 Keybanc
Overweight

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

FAQ

  • What is the ticker symbol for AbCellera Biologics?
  • Does AbCellera Biologics pay dividends?
  • What sector is AbCellera Biologics in?
  • What industry is AbCellera Biologics in?
  • What country is AbCellera Biologics based in?
  • When did AbCellera Biologics go public?
  • Is AbCellera Biologics in the S&P 500?
  • Is AbCellera Biologics in the NASDAQ 100?
  • Is AbCellera Biologics in the Dow Jones?
  • When was AbCellera Biologics's last earnings report?
  • When does AbCellera Biologics report earnings?
  • Should I buy AbCellera Biologics stock now?

What is the ticker symbol for AbCellera Biologics?

The ticker symbol for AbCellera Biologics is NASDAQ:ABCL

Does AbCellera Biologics pay dividends?

No, AbCellera Biologics does not pay dividends

What sector is AbCellera Biologics in?

AbCellera Biologics is in the Healthcare sector

What industry is AbCellera Biologics in?

AbCellera Biologics is in the Biotechnology industry

What country is AbCellera Biologics based in?

AbCellera Biologics is headquartered in Canada

When did AbCellera Biologics go public?

AbCellera Biologics's initial public offering (IPO) was on December 11, 2020

Is AbCellera Biologics in the S&P 500?

No, AbCellera Biologics is not included in the S&P 500 index

Is AbCellera Biologics in the NASDAQ 100?

No, AbCellera Biologics is not included in the NASDAQ 100 index

Is AbCellera Biologics in the Dow Jones?

No, AbCellera Biologics is not included in the Dow Jones index

When was AbCellera Biologics's last earnings report?

AbCellera Biologics's most recent earnings report was on Feb 27, 2025

When does AbCellera Biologics report earnings?

The next expected earnings date for AbCellera Biologics is May 7, 2025

Should I buy AbCellera Biologics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions